VivoSeq
Other

Hypoalbuminemia

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Hypoalbuminemia is an early-stage landscape with 6 programs across 4 companies. The most active players are Tonghua Anrate Biopharmaceutical Co., Ltd., Healthgen Biotechnology Corp., Bristol-Myers Squibb. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tonghua Anrate Biopharmaceutical Co., Ltd.

2 programs

Phase 3H

Healthgen Biotechnology Corp.

3 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

ApprovedD

Dexcel Pharma Technologies Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Withdrawn1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment
Not yet recruiting·HHealthgen Biotechnology Corp.·N/A·NCT07435922·2,000 enrolled
Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity
Completed·HHospital San Juan de la Cruz·Phase 3·NCT02708771·42 enrolled
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
Completed·HHealthgen Biotechnology Corp.·Phase 3·NCT06355479·328 enrolled
The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia
Completed·NNational Cheng-Kung University Hospital·Phase 4·NCT01822600·91 enrolled
A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites
Completed·TTonghua Anrate Biopharmaceutical Co., Ltd.·Phase 3·NCT06911554·416 enrolled
Hypoalbuminemia in Burn Patients
Withdrawn·—·Phase 4·NCT01436292

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)